Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 5/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23601163 | 0.84 | CNR2 (0.46) | CNR2RETPDE10AMAP4K4LRRK2 | |
| SCHEMBL24721010 | 0.81 | PSEN1 (0.44) | CNR2RETPDE10AMAP4K4 | |
| SCHEMBL24721149 | 0.77 | WNT3A (0.55) | CNR2RETPDE4APDE4BPDE4D | |
| SCHEMBL24721150 | 0.74 | RET (0.54) | RETLRRK2 | |
| SCHEMBL15034194 | 0.71 | HRH3 (0.55) | RETPDE10AMAP4K4 | |
| SCHEMBL24721532 | 0.71 | IDO1 (0.47) | MAP4K4ADORA2A | |
| SCHEMBL12093610 | 0.70 | HRH3 (0.57) | RETMAP4K4 | |
| SCHEMBL21588309 | 0.70 | MAP4K4 (0.48) | RETPDE10AMAP4K4ACACB | |
| SCHEMBL12236680 | 0.70 | MAP4K4 (0.54) | RETMAP4K4 | |
| SCHEMBL14694212 | 0.69 | MAP4K4 (0.51) | CNR2RETPDE10AMAP4K4ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | CNR2 1348/4885RET 1423/4885PDE4A 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.